ASK1 inhibitor treatment has been reported to be safe and efficacious to reduce liver fibrosis in a phase II trial of nonalcoholic steatohepatitis,44 while the results of a trial evaluating ASK1 inhibitor treatment in patients with diabetic kidney disease have yet to be reported. The gene discussed is MAP3K5; the disease is metabolic dysfunction-associated steatohepatitis.